SOHO State of the Art Updates and Next Questions: IDH Inhibition.
AML
Enasidenib
Ivosidenib
MDS
Targeted therapy
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
17
03
2021
revised:
23
04
2021
accepted:
03
05
2021
pubmed:
2
7
2021
medline:
9
2
2022
entrez:
1
7
2021
Statut:
ppublish
Résumé
There has been extraordinary progress in the field of targeted therapy for myeloid malignancies in the last few years, especially due to the approval of various agents that can be used as monotherapy or in combination as first-line treatment or when facing a refractory or relapsed disease. Many successful trials have been conducted recently, and a consistent body of work about the efficacy of novel molecules is now available. In this review, we sought to explain how enasidenib and ivosidenib have changed the face of myeloid neoplasm treatment through isocitrate dehydrogenase inhibition and to summarize the trials results that have led to the current commercial indications for the two molecules.
Identifiants
pubmed: 34193376
pii: S2152-2650(21)00180-4
doi: 10.1016/j.clml.2021.05.004
pii:
doi:
Substances chimiques
Aminopyridines
0
Pyridines
0
Triazines
0
enasidenib
3T1SS4E7AG
Isocitrate Dehydrogenase
EC 1.1.1.41
ivosidenib
Q2PCN8MAM6
Glycine
TE7660XO1C
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-572Informations de copyright
Copyright © 2021. Published by Elsevier Inc.